, /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present initial clinical data, with a focus on safety, exposure, and pharmacodynamic measures, from the monotherapy dose-escalation portion of the Phase 1 study of HST-1011, an oral, selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B), in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place , in . Presentation details are as follows: First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors Proffered Paper session: Investigational immunotherapy , Burgos Auditorium – Hall 5, Fira Barcelona Gran Via 991O HotSpot Therapeutics, Inc.
is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company's proprietary Smart AllosteryTM platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots wit.
